Discussion  by unknown
Discussion
Dr Alex G. Little (Dayton, Ohio). I think we would all agree that
any collection of this large number of patients deserves to be
analyzed and thought about carefully. That said, I am going to get
to three areas in which I have some questions. One is to make a
statement with which I know you agree because of having had the
opportunity to read your manuscript and your identification of the
limitations. The statement is that the validity of any clinical review
of patients with IA disease really is dependent on the accuracy of
the staging process that classified those patients. That being said,
I do not think the concern of some patients with actual stage III or
II disease being included weakens your conclusions, because pre-
sumably on a random basis the patients would have been evenly
distributed. However, I think it really undermines to the point of
negating any observations about long-term survival of patients
with IA disease because we just do not know that this is really a
clean collection of patients with stage IA disease. Would you
comment on that, please?
Dr Chang. Yes, I agree. If you look at the entire cohort, it is
difficult to reach the conclusion that 5-year survival is 58% be-
cause of this issue of understaging. I think some of the predictors
we looked at probably are valid. For example, there is no reason to
think that the men were understaged more than the women, so that
difference probably remains valid even if the numbers themselves
may be slightly higher in a carefully staged population of patients.
Dr Little. With that in mind, you might think about modifying
your manuscript and not being too declarative about the survival of
just patients with IA disease.
The second question has to do with the issue of the wedge
resections. There are wedge resections and then there are wedge
resections. Do you have any information about whether or not
there were frozen section analyses done of the margins? Do we
really know that those were “good” wedge resections?
Dr Chang. No, the database does not contain information on
margin status.
Dr Little. I do not think any of us really wants to stoutly defend
that being the ideal choice for lung cancer; nonetheless, the results
might have been better had those wedge resections been quality-
controlled.
Dr Chang. That is absolutely correct.
Dr Little. Finally, there is an old saying: A difference to be a
difference must make a difference. What difference does it make
to us as clinicians to have this information? Would you suggest
that patients with some number of these negative prognostic fac-
tors should be treated differently—not operated on, operated on
with smaller operations, receive multimodality therapy, either ad-
juvant therapy or neoadjuvant? What can we take home from this
that will affect our patient care?
Dr Chang. We do not suggest that these results are the best that
are achievable. Looking at carefully controlled and staged single-
institution studies would give us a better idea of what is the best
possible practice. What this does show is the current state within
the United States of patients who are deemed to have stage IA
disease, and I think these results raise the issue that many patients
are probably not being staged properly. I think understaging ac-
counts mostly for the difference in survival between this study and
single-institution studies.
Dr Little. I agree. Thank you.
Dr Nasser K. Altorki (New York, NY). I enjoyed your presen-
tation.
I have two questions. First, have you had an opportunity to look
at the effect of cell type, squamous versus nonsquamous histologic
types? Second, you have presented us, I presume, with overall
survival/all-cause mortality. Have you had an opportunity to look
at lung cancer–specific deaths?
Dr Chang. Thank you for your question. The data on cell type
are available in the SEER database. There were about 42% ade-
nocarcinomas and about 25% squamous cell carcinomas. How-
ever, we did not look at the impact of histology on survival. With
regard to all-cause mortality, there is a variable within the database
indicating the cause of death, but we believed that this was
probably a fairly unreliable variable because it is abstracted from
death certificates. Often, the cause of death on a death certificate is
listed as cardiac arrest or multisystem organ failure without any
autopsy data. We thought that that was probably a fairly unreliable
way to look at survival. Therefore, you are absolutely correct; this
is all-cause survival.
Dr Todd Demmy (Buffalo, NY). Regarding age, why did you
use 67 as your age dichotomizing cut point? Did you look at the
population of early emerging lung cancer? There have been reports
of patients presenting in their 40s and 50s with lung cancer having
a worse biological disease. Did you look at your data for the young
group of patients presenting with lung cancer?
Dr Chang. Thank you for your question, Dr Demmy. We did
not specifically look at the younger populations. We did analyze
age as a continuous variable, and age was a significant predictor of
survival. We chose to dichotomize age to make interpretation of
the results easier. But we did not go through and look at multiple
quintiles and specifically focus on the younger patients. However,
you are correct in that with a cohort of this size, we do have the
power to examine survival in the very young patients. This addi-
tional analysis would be very worthwhile.
Dr David H. Harpole, Jr (Durham, NC). I know that the
SEER data are localized. Did you look at any volume determinants
versus survival? In other words, did you look in the SEER set to
see the sites that were low volume versus high volume and see
whether that translated into a long-term survival difference? Along
the same vein, I think some SEER data have universal physician
identification numbers (UPIN). I do not know how much of that
information you have. Could you drill it down to type of surgeon?
We have thought about doing this in administrative databases
where you can look at the type of surgery done by the UPIN-
derived surgeon to see whether you could separate actually who
did the operation, because you may find that some of these wedges
were actually not high comorbid but maybe were not necessarily
done by a thoracic surgeon. That could be interesting data as well
if you are able to get that.
Dr Chang. Thank you for your question and comment. I am
not aware that the UPINs are available in the SEER database. I do
know that the hospital where the procedure was performed is not
available in the SEER database. Hospital identification information
is available in the SEER–Medicare database, which we have not
looked at. The downside of the SEER–included Medicare data-
base, of course, is that patients under age 65 are not in the
SEER–Medicare database.
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